BROOKLYN PARK, Minn., March 1, 2018 /PRNewswire/ — 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its medical device for mitral regurgitation (MR) will be highlighted in two presentations at the Cardiovascular Research Technologies (CRT) meeting held March 3-6, 2018 in Washington, DC. 4C Medical […]
Coronary/Structural Heart
Scandinavian Real Heart Selects AdaCore Embedded Software Development Platform for Revolutionary Artificial Heart
NEW YORK & PARIS & NUREMBERG, Germany–(BUSINESS WIRE)–Embedded World–AdaCore, a trusted provider of software development and verification tools with headquarters in New York and Paris, today announced that Scandinavian Real Heart AB in Sweden is using a suite of AdaCore software solutions to develop reliable embedded software for its revolutionary Total Artificial […]
REVA ANNOUNCES CE MARK AND FIRST IMPLANT OF THE FANTOM ENCORE BIORESORBABLE SCAFFOLD
2.5 millimeter Diameter Size with Market-Leading 95 micron Strut Profile Secures Early Approval San Diego, California (Monday, February 26, 2018 – PST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announces CE Mark of the 2.5 millimeter diameter size […]
Medtronic Launches First 2.0 mm Drug-Eluting Stent in United States Designed to Treat Patients with Small Vessels
FDA Approved, Resolute Onyx 2.0 mm DES Technology Tackles Clinical Challenge of Treating Coronary Artery Disease in Previously Untreatable Patients DUBLIN – February 26, 2018 – Designed specifically for small vessels, Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute […]
NaviGate Cardiac Structures Inc. (“NCSI”) reports GATE™ bioprosthesis as the first transcatheter valve replacement in Canada to treat tricuspid regurgitation
LAKE FOREST, Calif.–(BUSINESS WIRE)–NaviGate Cardiac Structures Inc. (“NCSI”) announced today that on 2 Feb. 2018, its catheter-guided GATE™ valved-stent bioprosthesis beame the first Canadian orthotopic valve replacement to treat severe tricuspid regurgitation. The procedure was performed at the Quebec Heart and Lung Institute, Laval University (Quebec City, Canada) by the Institute’s […]
Vascular Graft Solutions: External Stenting of Vein Grafts is Associated With High Early Patency Rates
TEL AVIV, Israel, Feb. 23, 2018 /PRNewswire/ — Vascular Grafts Solutions announced today the interim results from the VEST III study, a post-marketing trial which evaluates the effectiveness of the VEST technology (Venous External SupporT) in treatment of saphenous vein graft (SVG) disease after coronary artery bypass grafting. The Interim […]
Tricuspid Valve Repair Company 4Tech Inc. Appoints Tom Fleming as President and CEO, and Dr. Keith Dawkins as CMO
GALWAY, Ireland–(BUSINESS WIRE)– 4Tech Inc., a leader in the field of transcatheter tricuspid valve repair, announces changes in its leadership team: Tom Fleming will join the company as President and Chief Executive Officer (CEO), effective as of March 2018; and Keith D. Dawkins, M.D., has joined as Chief Medical Officer (CMO), effective immediately. Tom […]
Study Validates New Approach for Optimizing Endovascular Drug Delivery Using Stents with a Deployable Coating That Enhances Sirolimus Distribution Compared to Traditional DES
“This preclinical demonstration that stent deployment of microcrystalline drug in combination with a rapidly absorbable polymer, such as with MiStent, results in more uniform drug dosing that could lead to more rapid and uniform healing across the treated segment,” said David Kandzari, M.D., Director of Interventional Cardiology and Chief Scientific Officer, Piedmont […]
Catheter Precision Launches Clinical Trial for Its VIVO™ Non-Invasive Mapping System
Study Expected to Expand to Five Hospitals and Evaluate Accuracy of the VIVO System LEDGEWOOD, N.J., Feb. 20, 2018 /PRNewswire/ — Catheter Precision, Inc.. announces the initiation of a pivotal clinical trial to assess the accuracy and safety of the VIVO™ (View Into Ventricular Onset) Non-Invasive Mapping System. The VIVO system […]
Mitralign raises $10m
Mitralign raises $10m FEBRUARY 21, 2018 BY BRAD PERRIELLO, MassDevice Mitralign, which is looking to commercialize its namesake mitral valve treatment and pursue regulatory nods for its Trialign tricuspid valve device, said it raised nearly $10 million. The $9.8 million funding, of a hoped-for $30.2 million, came from 19 unnamed investors beginning […]
Recent
Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors
Corify Care Receives FDA Clearance for ACORYS® — Introducing Instant, 4-D Electroanatomical Cardiac Mapping in Real-time
Rapid Medical™ Announces FDA Clearance of TIGERTRIEVER™ 25 and First Clinical Cases
Popular
- No commented posts yet